The Mechanisms of Action of Lithium: I. Effects on Serotoninergic and Noradrenergic Systems in Normal Subjects

Archives of General Psychiatry

Volumn 48, Issue 6, 1991, Pages 505-512

  Manji, Husseini K ^a   Hsiao, John K ^a   Risby, Emile D ^a,b   Oliver, Jerry ^a   Rudorfer, Matthew V ^a   Potter, William Z ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; HYDROCORTISONE; LITHIUM; NORADRENALIN; PROLACTIN; SEROTONIN;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; VOLUNTEER;

ADULT; BLOOD PRESSURE; CLOMIPRAMINE; CORTICOTROPIN; FEMALE; HEART RATE; HUMAN; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; LITHIUM; LITHIUM CARBONATE; MALE; METHOXYHYDROXYPHENYLGLYCOL; NOREPINEPHRINE; NORMETANEPHRINE; PROLACTIN; RECEPTORS, ADRENERGIC; RECEPTORS, SEROTONIN; SEROTONIN; SYMPATHETIC NERVOUS SYSTEM; VANILMANDELIC ACID;

EID: 0025899642     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1991.01810300017003     Document Type: Article

References (111)

1. Bunney WE, Garland-Bunney BL. Mechanisms of action of lithium in affective illness: basic and clinical implications. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:553-565.
2. Wood AJ, Goodwin GM. A review of the biochemical and neuropharmacological actions of lithium. Psychol Med. 1987;17:579-600.
3. Sugrue MF. Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol Ther. 1983;21:1-33.
4. Davis JM, Bresnahan DB. Psychopharmacology in clinical psychiatry. In: Hales RE, Frances AJ, eds. American Psychiatric Association Annual Review. Washington, DC: American Psychiatric Press Inc; 1987:159-187.
5. Baraban JM, Worley PF, Snyder SH. Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium. Am J Psychiatry. 1989;146:1251-1260.
6. Risby ED, Hsiao JK, Manji HK, Bitran J, Moses F, Zhou DF, Potter WZ. The mechanisms of action of lithium, II: effects on adenylate cyclase activity and β-adrenergic receptor binding in normal subjects. Arch Gen Psychiatry. 1991;48:513-524.
7. de Montigny C, Chaput Y, Blier P. Lithium augmentation of antidepressant treatments: evidence for the involvement of the 5-HT system? In: Briley M, Fillion G, eds. New Concepts in Depression. New York, NY: Macmillan Publishing Co Inc; 1988:144-160.
8. Muller-Oerlinghausen B. Lithium long-term treatment: does it act via serotonin? Pharmacopsychiatry. 1985;18:214-217.
9. Price LH, Charney DS, Delgado PL, Heninger GR. Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology. 1990;100:3-12.
10. Knapp S, Mandell AJ. Effects of lithium chloride on parameters of biosynthetic capacity for 5-hydroxytryptamine in rat brain. J Pharmacol Exp Ther. 1975;193:812-823.
11. Berggren U. Effects of short-term lithium administration on tryptophan levels and 5-hydroxytryptamine synthesis in whole brain and brain regions in rats. J Neural Transm. 1987;69:115-121.
12. Swann AC, Heninger GR, Roth RH, Maas JW. Differential effects of short and long term lithium on tryptophan uptake and serotonergic function in cat brain. Life Sci. 1981;28:347-354.
13. Ho AKS, Loh HH, Craves F, Hitzemann RJ, Gershon S. The effect of prolonged lithium treatment on the synthesis rate and turnover of monoamines in brain regions of rats. Eur J Pharmacol. 1970;10:72-78.
14. Shukla GS. Combined lithium and valproate treatment and subsequent withdrawal: serotonergic mechanism of their interaction in discrete brain regions. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:153-156.
15. Ahluwalia P, Singhal RL. Effect of low-dose lithium administration and subsequent withdrawal on biogenic amines in rat brain. Br J Pharmacol. 1980;71:601-607.
16. Treiser SL, Cascio CS, O'Donohue TL, Thoa NB, Jacobowitz DM, Kellar KJ. Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science. 1981;213:1529-1531.
17. Wang H-Y, Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology. 1989;99:213-218.
18. Friedman E, Wang H-Y. Effect of chronic lithium treatment on 5-hydroxytryptamine autoreceptors and release of 5-[3H]hydroxytryptamine from rat brain cortical, hippocampal, and hypothalamic slices. J Neurochem. 1988;50:195-201.
19. Treiser S, Kellar KJ. Lithium: effects on serotonin receptors in rat brain. Eur J Pharmacol. 1980;64:183-185.
20. Maggi A, Enna SJ. Regional alterations in rat brain neurotransmitter systems following chronic lithium treatment. J Neurochem. 1980;34:888-892.
21. de Montigny C, Grunberg F, Mayer A, Deschenes J-P. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry. 1981;138:252-256.
22. de Montigny C, Cournoyer G, Morissette R, Langlois R, Caille G. Lithium carbonate addition in tricyclic antidepressant—resistant depression: correlations with the neurobiologic action of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry. 1983;40:1327-1334.
23. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatmentrefractory depression. Arch Gen Psychiatry. 1983;40:1335-1342.
24. Garbutt JC, Mayo JP, Gillette GM, Little KY, Mason GA. Lithium potentiation of tricyclic antidepressants following lack of T3 potentiation. Am J Psychiatry. 1986;143:1038-1039.
25. Kramlinger KG, Post RM. The addition of lithium to carbamazepine: antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry. 1989;46:794-800.
26. Berrettini WH, Nurnberger JI, Scheinin M, Seppala T, Linnoila M, Narrow W, Simmons-Alling S, Gershon ES. Cerebrospinal fluid and plasma monoamines and their metabolites in euthymic bipolar patients. Biol Psychiatry. 1985;20:257-269.
27. Fryo B, Petterson U, Sedvall G. The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patients. Psychopharmacology. 1975;44:99-103.
28. Bowers MB, Heninger GR. Lithium: clinical effects and cerebrospinal fluid acid monoamine metabolites. Communications Psychopharmacol. 1977;1:135-145.
29. Swann AC, Koslow SH, Katz MM, Maas JW, Javaid J, Secunda SK, Robins E. Lithium carbonate treatment of mania. Arch Gen Psychiatry. 1987;44:345-354.
30. Glue PW, Cowen PJ, Nutt DJ, Kolakowska T, Grahame-Smith DG. The effect of lithium on 5-HT mediated neuroendocrine response and platelet 5-HT receptors. Psychopharmacology. 1986;90:398-402.
31. Meltzer HY, Arora RC, Goodnick P. Effect of lithium carbonate on serotonin uptake in blood platelets of patients with affective disorders. J Affective Disord. 1983;5:215-221.
32. Coppen A, Swade C, Wood K. Lithium restores abnormal platelet 5-HT transport in patients with affective disorders. Br J Psychiatry. 1980;136:235-238.
33. Born GVR, Grignani G, Martin K. Long-term effect of lithium on the uptake of 5-hydroxytryptamine by human platelets. Br J Clin Pharmacol. 1980;9:321-325.
34. Poirer MF, Galzin AM, Pimoule C, Schoemaker H, Le Quan Bui KH, Meyer P, Gay C, Loo H, Langer SZ. Short-term lithium administration to healthy volunteers produces long-lasting pronounced changes in platelet serotonin uptake but not imipramine binding. Psychopharmacology. 1988;94:521-526.
35. Wood K, Swade C, Abou-Saleh MT, Coppen A. Apparent supersensitivity of platelet 5-HT receptors in lithium-treated patients. J Affective Disord. 1985;8:69-72.
36. Slater S, de la Vega CE, Skyler J, Murphy DL. Plasma prolactin stimulation by fenfluramine and amphetamine. Psychopharmacol Bull. 1976;12:26-27.
37. McCance Si, Cohen PR, Cowen PJ. Lithium increases 5-HT-mediated prolactin release. Psychopharmacology. 1989;99:276-281.
38. Cowen PJ, McCance SL, Cohen PR, Julier DL. Lithium increases 5-HT-mediated neuroendocrine responses in tricyclic resistant depression. Psychopharmacology. 1989;99:230-232.
39. Meltzer HY, Lowy M, Robertson A, Goodnick P, Perline R. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders, III: effect of antidepressants and lithium carbonate. Arch Gen Psychiatry. 1984;41:391-397.
40. Muhlbauer HD, Muller-Oerlinghausen B. Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man. J Neural Transm. 1985;61:81-94.
41. Price LH, Charney DS, Delgado PL, Heninger GR. Lithium treatment and serotonergic function. Arch Gen Psychiatry. 1989;46:13-19.
42. Muhlbauer HD. The influence of fenfluramine stimulation on prolactin plasma levels in lithium long-term-treated manic-depressive patients and healthy subjects. Pharmacopsychiatry. 1984;17:191-193.
43. Corrodi H, Fuxe K, Hokfelt T, Schou M. The effect of lithium on cerebral monoamine neurons. Psychopharmacology. 1967;11:345-353.
44. Schildkraut JJ, Logue MA, Dodge GA. The effects of lithium salts on the turnover and metabolism of norepinephrine in rat brain. Psychopharmacology. 1969;14:135-141.
45. Schildkraut JJ, Schanberg SM, Kopin IJ. The effects of lithium ion on 3H-norepinephrine metabolism in brain. Life Sci. 1966;16:1479-1483.
46. Ahluwalia P, Singhal RL. Monoamine uptake into synaptosomes from various regions of rat brain following lithium administration and withdrawal. Neuropharmacology. 1981;20:483-487.
47. Stern DN, Fieve RR, Neff NH, Costa E. The effect of lithium chloride administration on brain and heart norepinephrine turnover rates. Psychopharmacology. 1969;14:315-322.
48. Poitou P, Bohuon C. Catecholamine metabolism in the rat brain after short and long term lithium administration. J Neurochem. 1975;25:535-537.
49. Katz RI, Chase TN, Kopin IJ. Evoked release of norepinephrine and serotonin from brain slices: inhibition by lithium. Science. 1968;162:466-467.
50. Katz RI, Kopin IJ. Release of 3H-norepinephrine and 3H-serotonin evoked from brain slices by electric field stimulation: calcium dependence and the effects of lithium and tetrodotoxin. Biochem Pharmacol. 1969;18:1935-1939.
51. Cameron OG, Smith CB. Comparison of acute and chronic lithium treatment on 3H-norepinephrine uptake by rat brain slices. Psychopharmacology. 1980;67:81-85.
52. Colburn RW, Goodwin FK, Bunney WE Jr, Davis JM. Effect of lithium on the uptake of noradrenaline by synaptosomes. Nature. 1967;215:1395-1397.
53. Kuriyama K, Speken R. Effect of lithium on content and uptake of norepinephrine and 5-hydroxytryptamine in mouse brain synaptosomes and mitochondria. Life Sci. 1970;9:1213-1220.
54. Linnoila M, Karoum F, Rosenthal N, Potter WZ. Electroconvulsive treatment and lithium carbonate. Arch Gen Psychiatry. 1983;40:677-680.
55. Schildkraut JJ. The effects of lithium on norepinephrine turnover and metabolism: basic and clinical studies. J Nerv Ment Dis. 1974;158:348-360.
56. Greenspan K, Schildkraut JJ, Gordon EK, Baer L, Aronoff MS, Durell J. Catecholamine metabolism in affective disorders, III: MHPG and other catecholamine metabolites in patients treated with lithium carbonate. J Psychiatr Res. 1970;7:171-183.
57. Beckmann H, St Laurent J, Goodwin FK. The effect of lithium on urinary MHPG in unipolar and bipolar depressed patients. Psychopharmacology. 1975;42:277-282.
58. Schildkraut JJ. The effects of lithium on norepinephrine turnover and metabolism: basic and clinical studies. In: Gershon S, Shopsin B, eds. Lithium: Its Role in Psychiatric Research and Treatment. New York, NY: Plenum Press; 1973:51-73.
59. Corona GL, Cucchi ML, Santagostino G, Frattini P, Zerbi F, Fengolio L, Savoldi F. Blood noradrenaline and 5-HT levels in depressed women during amitriptyline or lithium treatment. Psychopharmacology. 1982;77:236-241.
60. Murphy DL, Lake CR, Slater S, Lipper S, Shiling D, de la Vega E, Zeigler MG. Psychoactive drug effects on plasma norepinephrine and plasma dopamine β-hydroxylase in man. In: Usdin E, Kopin IJ, Barchas J, eds. Catecholamines: Basic and Clinical Frontiers. Elmsford, NY: Pergamon Press Inc; 1979:918-920.
61. Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter WZ. The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab. 1989;68:632-637.
62. Laakman G, Chuang I, Gugath M, Ortner M, Schmauss M, Wittman M. Prolactin and antidepressants. In: Tolis G, Stefanis C, Mountokalakis T, Labrie F, eds. Prolactin and Prolactinomas. New York, NY: Raven Press; 1983:151-161.
63. Golden RN, Hsiao JK, Lane E, Ekstrom D, Rogers S, Hicks R, Potter WZ. Abnormal neuroendocrine responsivity to acute intravenous clomipramine challenge in depressed patients. Psychiatry Res. 1990;31:39-47.
64. Rudorfer MV, Karoum F, Ross RJ, Potter WZ, Linnoila M. Differences in lithium effects in depressed and healthy subjects. Clin Pharmacol Ther. 1985;37:66-71.
65. Cooper TB, Bergner PE, Simpson GM. The 24-hour serum lithium level as a prognosticator of dosage requirements. Am J Psychiatry. 1973;130:601-603.
66. Huynh H, Feldt LS. Estimation of the Box correction for degrees of freedom from sample data in the randomized block and split plot design. J Educ Stat. 1976;1:69-82.
67. Chang WH, Scheinin M, Burns RS, Linnoila M. Rapid and simple determination of homovanillic acid in plasma using high performance liquid chromatography with electrochemical detection. Acta Pharmacol Toxicol. 1983;53:275-279.
68. Seppala T, Scheinin M, Capone A, Linnoila M. Liquid chromatographic assay for CSF catecholamines using electrochemical detection. Acta Pharmacol Toxicol. 1984;55:81-87.
69. Scheinin M, Chang WH, Jimerson DC, Linnoila M. Measurement of 3-methoxy-4-hydroxyphenylglycol in human plasma with high-performance liquid chromatography using electrochemical detection. Anal Biochem. 1983;132:165-170.
70. Gordon E, Oliver J, Black K, Kopin IJ. Simultaneous assay by mass fragmentography of vanillylmandelic acid, homovanillic acid, and 3-methoxy-4-hydroxyphenylethylene glycol in cerebrospinal fluid and urine. Biochem Med. 1974;11:32-40.
71. Karoum F, Neff N. Quantitative gas chromatography-mass spectrometry (GC-MS) of biogenic amines: theory and practice. In: Spector S, Beck N, eds. Modern Methods in Pharmacology. New York, NY: Alan R Liss Inc; 1982:39-54.
72. Karoum F, Chuang L, Wyatt RJ. On the enzymatic hydrolysis of the sulfate conjugate of 3-methoxy-4-hydroxyphenylglycol (MHPG). Biochem Med. 1980;24:314-320.
73. Meltzer HY, Gudelsky GA, Koenig J. Antipsychotics, tricyclic antidepressants, and lithium. In: Nomoroff CB, Loosen PT, eds. Handbook of Clinical Psychoneuroendocrinology. New York, NY: Guilford Press; 1982:266-292.
74. van Praag HM, Lemus C, Kahn R. Hormonal probes of central serotonergic activity: do they really exist? Biol Psychiatry. 1987;22:86-98.
75. Wang HY, Friedman E. Chronic lithium: desensitization of auroreceptors mediating serotonin release. Psychopharmacology. 1988;94:312-314.
76. Hotta I, Yamawaki S. Possible involvement of presynaptic 5-HT autoreceptors in effect of lithium on 5-HT release in hippocampus of rat. Neuropharmacology. 1988;27:987-992.
77. Bond PA, Jenner JA, Sampson DA. Daily variation of the urine content of 3-methoxy-4-hydroxyphenylglycol in two manic-depressive patients. Psychol Med. 1972;2:81-85.
78. Jones FD, Maas JW, Dekirmenjian M, Fawcett JA. Urinary catecholamine metabolites during behavioural changes in a patient with manic-depressive cycles. Science. 1973;179:300-302.
79. Post RM, Stoddard FJ, Gillin JC, Buchsbaum MS, Runkle DC, Black KE, Bunney WE. Alterations in motor activity, sleep, and biochemistry in a cycling manic-depressive patient. Arch Gen Psychiatry. 1977;34:470-477.
80. Schildkraut JJ, Keeler BA, Grab EL, Kantrowich J, Kartmann E. MHPG excretion and clinical classification in depressive disorders. Lancet. 1973;1:1251-1252.
81. Wehr TA. Phase and biorhythm studies in affective illness. Ann Intern Med. 1977;87:319-335.
82. Grof E, Brown GM, Grof P, Van Loon GR. Effects of lithium administration on plasma catecholamines. Psychiatry Res. 1986;19:87-92.
83. Goodwin GM, DeSouza RJ, Wood AJ, Green AR. Lithium decreases 5-HT1A and 5-HT2 receptor and alpha-2-adrenoceptor mediated function in mice. Psychopharmacology. 1986;90:482-487.
84. Spengler RN, Hollingsworth PJ, Smith CB. Effects of long-term lithium and desipramine treatment upon clonidine-induced inhibition of 3H-norepinephrine release from rat hippocampal slices. Fed Proc. 1986;45:681.
85. Smith DF. Lithium attenuates clonidine-induced hypoactivity: further studies in inbred mouse strains. Psychopharmacology. 1988;94:428-430.
86. Ebstein RP, Lerer B, Shlaufman M, Belmaker RH. The effect of repeated electroconvulsive shock treatment and chronic lithium feeding on the release of norepinephrine from rat cortical vesicular preparations. Cell Mol Neurobiol. 1983;3:191-201.
87. Goodnick PJ, Meltzer HY. Neurochemical changes during discontinuation of lithium prophylaxis, I: increases in clonidine-induced hypotension. Biol Psychiatry. 1984;19:883-889.
88. Wood K, Coppen A. Prophylactic lithium treatment of patients with affective disorder is associated with decreased platelet 3H-dihydroergocryptine binding. J Affective Disord. 1983;5:253-258.
89. Garcia-Sevilla JA, Guimon J, Garcia-Vallejo P, Fuster MJ. Biochemical and functional evidence of supersensitive platelet alpha-2-adrenoceptors in major affective disorder: effect of long-term lithium carbonate treatment. Arch Gen Psychiatry. 1986;43:51-57.
90. Pandey GN, Janicak PG, Javaid JI, Davis JM. Increased 3H-clonidine binding in the platelets of patients with depressive and schizophrenic disorders. Psychiatry Res. 1989;28:73-88.
91. Smith CB, Hollingsworth PJ, Garcia-Sevilla JA, Zis AP. Platelet alpha-2 adrenoreceptors are decreased in number after antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry. 1983;7:241-247.
92. Catalano M, Bellodi L, Lucca A, Brambilla F. Lithium and alpha-2-adrenergic receptors: effects of lithium ion on clonidine-induced growth hormone release. Neuroendocrinol Lett. 1984;6:61-65.
93. Brambilla F, Catalano M, Lucca A, Smeraldi E. Effect of lithium treatment on the GH-clonidine test in affective disorders. Eur J Clin Pharmacol. 1988;35:601-605.
94. Huey LY, Janowsky DS, Judd LL, Abrams A, Parker D, Clopton P. Effects of lithium carbonate on methylphenidate-induced mood, behaviour, and cognitive processes. Psychopharmacology. 1981;73:161-164.
95. Murphy DL, Donnelly C, Moskowitz J. Inhibition by lithium of prostaglandin E1 and norepinephrine effects on cyclic adenosine monophosphate production in human platelets. Clin Pharmacol Ther. 1974;14:810-814.
96. Starke K. Presynaptic alpha-autoreceptors. Rev Physiol Biochem Pharmacol. 1987;107:73-146.
97. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev. 1981;32:332-362.
98. Bartko JJ, Pulver AE, Carpenter WT. The power of analysis: statistical perspectives, II. Psychiatry Res. 1988;23:301-309.
99. Esler M. Assessment of sympathetic nervous function in humans from noradrenaline plasma kinetics. Clin Sci. 1982;62:247-254.
100. Kopin IJ. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev. 1985;37:333-364.
101. Robinson DS, Johnson GA, Nies A, Corcella J, Cooper TB, Albright D, Howard D. Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. J Clin Psychopharmacol. 1983;3:282-287.
102. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ. Plasma dihydroxyphenylglycol and the intraneuronal disposition of noradrenaline in humans. J Clin Invest. 1988;81:213-220.
103. Eisenhofer G, Goldstein DS, Ropchak TG, Nguyen HQ, Keiser HR, Kopin IJ. Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J Auton Nerv Syst. 1988; 24:1-14.
104. Ross RJ, Scheinin M, Lesieur P, Rudorfer MV, Hauger RL, Siever LJ, Linnoila M, Potter WZ. The effect of clorgyline on noradrenergic function. Psychopharmacology. 1985;85:227-230.
105. Major LF, Murphy DL, Lipper S, Gordon E. Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem. 1985;45:949-956.
106. Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ. Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients. Arch Gen Psychiatry. 1982;39:513-516.
107. Rudorfer MV, Scheinin M, Karoum F, Ross RJ, Potter WZ, Linnoila M. Reduction of norepinephrine turnover by serotonergic drug in man. Biol Psychiatry. 1984;19:179-193.
108. Goldstein DS, Stull R, Eisenhofer G, Gill JR. Urinary excretion of dihydroxyphenylalanine and dopamine during alterations of dietary salt intake in humans. Clin Sci. 1989;76:517-522.
109. Maas JW, Leckman JF. Relationships between CNS noradrenergic function in plasma and urinary MHPG and other metabolites. In: Maas JW, ed. MHPG: Basic Mechanisms and Psychopathology. Orlando, Fla: Academic Press Inc; 1983:33-43.
110. Esler M. Renal catecholamine metabolism. Miner Electrolyte Metab. 1989;115:16-23.
111. Stephenson RK, Sole MJ, Baines AD. Neural and extraneural catecholamine production by rat kidneys. Am J Physiol. 1982;242:F261-F266.